Granisetron plus dexamethasone may increase arrhythmia risk
the ONA take:
According to two studies published online ahead of print in the journal BMC Medicine, researchers have found that granisetron, a serotonin 5HT3 receptor antagonist, plus dexamethasone may increase a patient's risk for developing an arrhythmia.
Most arrhythmias are no serious; however, some put patients at a higher risk for stroke, heart failure, or cardiac arrest.
Serotonin receptor antagonists, such as granisetron, ondansetron, and palonosetron, are commony used to reduce nausea and vomiting in patients receiving moderately or highly emetogenic chemotherapy, as well as in those undergoing surgery.
Results of the studies showed that the safest serotonin receptor antagonists in combination with a steroid with respect to arrhythmia were ondansetron plus dexamethasone, and dolasetron for patients of all ages.
The studies were conducted in patients undergoing anesthesia for surgery.
Granisetron plus dexamethasone may increase a patient's risk for developing an arrhythmia.
- Physical Activity Improves Outcomes for Patients with Breast Cancer and Survivors
- Behavior Pain Assessment Tool Measures Pain In Patients Who Cannot Communicate Verbally
- Whole Genome Sequencing Reveals that 12% of Childhood Cancer Survivors Have Mutations in Genes that Increase Cancer Risk
- Increased 5-Year Survival Rate Seen in NSCLC Subset Treated With Nivolumab
- Novel Test For Multiple Myeloma Uses Microchip, Conventional Blood Sample
- Exercise, Psychological Interventions Better for Cancer Fatigue Than Medications
- ASCO Issues Global Guidance for HPV Vaccination for Cervical Cancer Prevention
- Discharge Events Improved With Standardized Inpatient Palliative Care Consultation
- Little Opposition to Early Palliative Care for Symptom Management in Pediatric Oncology
- Updated ASTRO Guideline Bolsters Safety, Efficacy of Palliative RT for Bone Metastases
- Thyroid Cancer Incidence Increasing Among Younger, Hispanic, African American Populations
- JAK1, JAK2 Inhibition Improves Outcomes in Myeloproliferative Neoplasms, But More Is Needed
- Recommendations Against Contralateral Prophylactic Mastectomy Not Tied to Patient Satisfaction
- Self-efficacy Level Predictive of Likelihood to Follow Through With Colorectal Cancer Screening
- Chronic Myeloproliferative Neoplasms Treatment (Fact Sheet)
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|